1 |
NCT03408860 |
Recruiting |
Isolating Mechanisms in the Treatment of Borderline Personality Disorder |
- Borderline Personality Disorder
|
- Other: Countering Emotional Behaviors Module from Unified Protocol
|
Interventional |
Not Applicable |
- Boston University Charles River Campus
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Multidimensional Experiential Avoidance Questionnaire
- Zanarini Rating Scale for BPD
|
8 |
All |
18 Years and older (Adult, Senior) |
NCT03408860 |
3842 K23MH106648-03 |
|
October 15, 2017 |
November 2018 |
November 2018 |
January 24, 2018 |
January 24, 2018 |
|
- Boston University Center for Anxiety and Related Disorders
Boston, Massachusetts, United States
|
2 |
NCT01353313 |
Recruiting |
Hydrocortisone for BPD |
- Infant, Newborn
- Infant, Small for Gestational Age
- Infant, Very Low Birth Weight
- (and 2 more...)
|
- Drug: Hydrocortisone
- Drug: Placebo
|
Interventional |
Phase 3 |
- NICHD Neonatal Research Network
- National Center for Research Resources (NCRR)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Efficacy
- Safety
- Morbidity and Growth
- (and 3 more...)
|
800 |
All |
up to 30 Weeks (Child) |
NCT01353313 |
NICHD-NRN-0045 U10HD034216 U10HD027904 U10HD021364 U10HD027853 U10HD040689 U10HD040492 U10HD027851 U10HD021373 U10HD027856 U10HD053109 U10HD036790 U10HD027880 U10HD053089 U10HD021385 U10HD068244 U10HD068263 U10HD068270 U10HD068278 U10HD068284 U24HL137729 1UG3HL137872 |
|
September 2011 |
January 2020 |
January 2025 |
May 13, 2011 |
December 15, 2017 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of California - Los Angeles
Los Angeles, California, United States - Stanford University
Palo Alto, California, United States - (and 17 more...)
|
3 |
NCT02527798 |
Recruiting |
Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD) |
- Bronchopulmonary Dysplasia
|
- Drug: Furosemide Cohort 1
- Drug: Furosemide Cohort 2
- Drug: Furosemide Cohort 3
- Other: Placebo
|
Interventional |
Phase 2 |
- University of North Carolina, Chapel Hill
- Duke University
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- The EMMES Corporation
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Safety as determined by adverse event experienced by participants. Description of safety of furosemide in premature infants at risk of BPD
- Change in moderate-severe BPD or death risk from baseline
- Clearance
- (and 4 more...)
|
120 |
All |
up to 28 Days (Child) |
NCT02527798 |
15-1978 HHSN27500033 HHSN27500035 5R01FD005101-02 |
|
August 2015 |
June 2019 |
June 2020 |
August 19, 2015 |
April 19, 2018 |
|
- Arkansas Children's Hospital/University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Loma Linda University Medical Center
Loma Linda, California, United States - Childrens National Medical Center
Washington, District of Columbia, United States - (and 17 more...)
|
4 |
NCT02751632 |
Recruiting |
The Staged Treatment in Early Psychosis Study |
- Psychotic Disorders
- Personality Disorders
|
- Behavioral: Support and Problem Solving Therapy
- Behavioral: Cognitive Behavioural Case Management
- Drug: Fluoxetine
- (and 2 more...)
|
Interventional |
Phase 3 |
- Orygen Youth Health Research Centre
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Global Functioning Scale Score
- Comprehensive Assessment of At Risk Mental State score
- Scale for Assessment of Negative Symptoms score
- Montgomery Asberg Depression Rating Scale score
|
340 |
All |
12 Years to 25 Years (Child, Adult) |
NCT02751632 |
2015.173 1U01MH105258-01 |
STEP |
April 2016 |
June 2019 |
December 2021 |
April 26, 2016 |
March 22, 2018 |
|
- Headspace
Craigieburn, Victoria, Australia - Headspace
Glenroy, Victoria, Australia - Orygen Youth Health Clinical Program
Melbourne, Victoria, Australia - (and 2 more...)
|
5 |
NCT01780155 |
Recruiting |
Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity |
- Bronchopulmonary Dysplasia
- Retinopathy of Prematurity
- Prematurity
- Pulmonary Disease
|
|
Observational |
|
- National Institute of Environmental Health Sciences (NIEHS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
- Bronchopulmonary dysplasia; retinopathy of prematurity
|
3600 |
All |
Child, Adult, Senior |
NCT01780155 |
999913031 13-E-N031 |
|
January 29, 2013 |
July 15, 2018 |
July 15, 2018 |
January 30, 2013 |
January 10, 2018 |
|
- NIEHS, Research Triangle Park
Research Triangle Park, North Carolina, United States - Clinica Y Maternidad
Suizo, Argentina
|
6 |
NCT02784821 |
Recruiting |
Antibiotic "Dysbiosis" in Preterm Infants |
- Enterocolitis, Necrotizing
- Bacteremia
- Bronchopulmonary Dysplasia
- (and 5 more...)
|
- Drug: Antibiotic
- Other: Gastric fluid
- Other: Breast milk
- (and 3 more...)
|
Interventional |
Phase 2 |
- University of Florida
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Society for Pediatric Dermatology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rates of necrotizing enterocolitis(NEC)
- Rates of bacteremia
- Microbiota 16s ribosomal ribonucleic acid (rRNA) metagenomic sequencing
- (and 13 more...)
|
420 |
All |
23 Weeks to 33 Weeks (Child) |
NCT02784821 |
IRB201501045-N R21HD088005 |
|
January 2017 |
September 2018 |
December 2018 |
May 27, 2016 |
April 23, 2018 |
|
- University of Florida
Gainesville, Florida, United States
|
7 |
NCT01880957 |
Recruiting |
PET and MRI Brain Imaging of Bipolar Disorder |
- Bipolar Disorder
- Bipolar Depression
- Unipolar Depression
|
- Drug: Lithium
- Drug: Lamotrigine
|
Interventional |
Not Applicable |
- Stony Brook University
- National Institute of Mental Health (NIMH)
- The Dana Foundation
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Hamilton Depression Rating Scale
|
76 |
All |
18 Years to 65 Years (Adult) |
NCT01880957 |
2012-1826-F 7R01MH090276-03 |
|
August 2012 |
May 2017 |
|
June 19, 2013 |
July 19, 2016 |
|
- Stony Brook University
Stony Brook, New York, United States
|
8 |
NCT02206945 |
Recruiting |
Neurofeedback for Obsessive-Compulsive Disorder (OCD) |
- Obsessive-Compulsive Disorder
|
- Behavioral: neurofeedback
- Behavioral: control feedback
|
Interventional |
Not Applicable |
- Yale University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- A modified version of the Yale-Brown Obsessive-Compulsive Symptom scale (Y-BOCS) will be used, that queries subjects regarding symptoms
- Control over target brain area
- Control over the target brain area.
|
54 |
All |
18 Years to 65 Years (Adult) |
NCT02206945 |
0206017435-2 R01MH100068 |
|
July 2015 |
May 2019 |
July 2019 |
August 1, 2014 |
February 6, 2018 |
|
- Yale University School of Medicine
New Haven, Connecticut, United States
|
9 |
NCT02421315 |
Recruiting |
Overlapping Neural Circuits in Pediatric OCD |
- Obsessive Compulsive Disorder
|
- Behavioral: Exposure & Response Prevention (EX/RP) and when indicated medication treatment
|
Interventional |
Not Applicable |
- New York State Psychiatric Institute
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Change from baseline in brain activation (fMRI) after therapy
- Change from baseline in fractional anisotropy (Diffusion tensor imaging) after therapy
- Probabilistic Go/No-go reinforcement learning task
- (and 2 more...)
|
80 |
All |
5 Years to 17 Years (Child) |
NCT02421315 |
7006 R21MH101441 |
|
October 2014 |
May 2018 |
May 2018 |
April 20, 2015 |
February 14, 2018 |
|
- NY State Psychiatric Institute
New York, New York, United States
|
10 |
NCT03447548 |
Recruiting |
Neurofeedback Training for High Risk Psychosis |
|
- Behavioral: Neurofeedback processing speed training
- Behavioral: Active control
|
Interventional |
Not Applicable |
- Hartford Hospital
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change on the Wechsler Intelligence Scale Processing Speed Index
|
105 |
All |
12 Years to 25 Years (Child, Adult) |
NCT03447548 |
HHC-2017-0190 1R33MH111850-01A1 |
|
March 1, 2018 |
December 1, 2020 |
January 1, 2021 |
February 27, 2018 |
February 27, 2018 |
|
- Connecting Adolescents with Psychosis (CAP), Child & Adolescents Day Program
Hartford, Connecticut, United States - Olin Neuropsychiatry Research Center
Hartford, Connecticut, United States
|
11 |
NCT01956344 |
Recruiting |
Neural Mechanisms of CBT Response in Hoarding Disorder |
- Obsessive Compulsive Disorder
|
- Behavioral: Cognitive Behavioral Therapy
|
Interventional |
Not Applicable |
- Hartford Hospital
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Saving Inventory-Revised (SI-R)
- Clinician Global Impression (CGI) Severity (Self Report and Clinician Administered)
|
120 |
All |
20 Years to 60 Years (Adult) |
NCT01956344 |
1R01MH101163-01 |
|
July 2013 |
June 2018 |
June 2018 |
October 8, 2013 |
March 14, 2018 |
|
- Anxiety Disorders Center, Institute of Living
Hartford, Connecticut, United States
|
12 |
NCT03333161 |
Recruiting |
Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 2 |
|
- Diagnostic Test: Cardiorespiratory monitoring
|
Interventional |
Not Applicable |
- University of Alabama at Birmingham
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hypoxemic episode
- Bradycardic episode
- Apnea episodes
- (and 2 more...)
|
25 |
All |
up to 15 Days (Child) |
NCT03333161 |
UAB Neo 017 U01HL133536 |
|
April 4, 2018 |
May 30, 2020 |
December 30, 2020 |
November 6, 2017 |
April 9, 2018 |
|
- Regional Neonatal ICU and CCN, University of Alabama at Birmingham
Birmingham, Alabama, United States
|
13 |
NCT02922335 |
Recruiting |
Multisystemic Therapy-Emerging Adults Trial |
|
- Behavioral: Multisystemic Therapy for Emerging Adults
- Behavioral: Enhanced Treatment as Usual
|
Interventional |
Not Applicable |
- University of Massachusetts, Worcester
- National Institute of Mental Health (NIMH)
- Oregon Social Learning Center
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in number and severity of criminal charges in official records in the 16 months pre-baseline compared with the 16 months post-baseline.
- Changes from Baseline scores compared to 16 months post-Baseline Self-efficacy (measured at 0,2,4,6,8,12 and 16 months).
- Changes from Baseline scores compared to 16 months post-Baseline Goal directness (measured at 0,2,4,6,8,12 and 16 months).
- (and 10 more...)
|
240 |
All |
17 Years to 21 Years (Child, Adult) |
NCT02922335 |
H0009053 1R01MH108793-01 |
MST-EA |
September 2016 |
March 2020 |
March 2020 |
October 4, 2016 |
March 22, 2018 |
|
- North American Family Institute
Hartford, Connecticut, United States - North American Family Institute
New Haven, Connecticut, United States
|
14 |
NCT00006177 |
Recruiting |
Child & Adolescent Bipolar Disorder Brain Imaging and Treatment Study |
- Healthy
- Bipolar Disorder
- Mood Disorders
|
|
Observational |
|
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
2300 |
All |
42 Months to 17 Years (Child) |
NCT00006177 |
000198 00-M-0198 |
|
August 11, 2000 |
|
|
August 14, 2000 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
15 |
NCT03239210 |
Recruiting |
Effects of Ondansetron in Obsessive-compulsive and Tic Disorders |
- Obsessive-Compulsive Disorder
- Tic Disorders
- Tourette Syndrome
|
- Drug: Ondansetron
- Drug: Placebo
|
Interventional |
Phase 4 |
- New York University School of Medicine
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Sensory phenomena severity from baseline to 4 weeks
- Percent BOLD signal change
- Patient-Related Inventory of Side effects
|
60 |
All |
18 Years to 60 Years (Adult) |
NCT03239210 |
17-01608 |
|
June 16, 2017 |
April 2020 |
April 2020 |
August 3, 2017 |
February 26, 2018 |
|
- New York University School of Medicine
New York, New York, United States - The Nathan S. Kline Institute for Psychiatric Research
New York, New York, United States
|
16 |
NCT03457675 |
Recruiting |
Development of Adaptive Deep Brain Stimulation for OCD |
- Obsessive-Compulsive Disorder
|
- Device: Activa PC+S DBS implant for OCD
- Other: One Month Blinded Discontinuation Period
|
Interventional |
Not Applicable |
- Baylor College of Medicine
- University of Pittsburgh
- Brown University
- (and 3 more...)
|
Other / NIH / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percent of subjects that display biomarkers of OCD-related distress
- Percent of subjects that display biomarkers of DBS-induced hypomania
- Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Rating OCD Symptom Severity
|
2 |
All |
21 Years to 70 Years (Adult, Senior) |
NCT03457675 |
H40255 1UH3NS100549 49340 |
|
March 2018 |
June 2022 |
June 2023 |
March 7, 2018 |
March 8, 2018 |
|
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States - Brown University
Providence, Rhode Island, United States - Baylor College of Medicine
Houston, Texas, United States
|
17 |
NCT03169881 |
Recruiting |
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants |
- Neurocognitive
- Neuroprotective
- Neonatal
- Neurodevelopmental Impairment
|
- Drug: Darbepoetin
- Drug: Placebo
|
Interventional |
Phase 3 |
- NICHD Neonatal Research Network
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Composite cognitive score on Bayley Scale of Infant Development III
- Death
- Cerebral Palsy
- (and 14 more...)
|
650 |
All |
23 Weeks to 28 Weeks (Child) |
NCT03169881 |
NICHD-NRN-0058 |
Darbe |
September 20, 2017 |
September 2022 |
September 2023 |
May 30, 2017 |
November 6, 2017 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Stanford University
Palo Alto, California, United States - Emory University
Atlanta, Georgia, United States - (and 13 more...)
|
18 |
NCT00575081 |
Recruiting |
Physiological Brain Atlas Development |
- Parkinson's Disease
- Obsessive Compulsive Disorder
- Dystonia
- (and 2 more...)
|
- Device: Stereotactic brain procedures
|
Observational |
|
- Vanderbilt University Medical Center
- National Institute for Biomedical Imaging and Bioengineering (NIBIB)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- To create an atlas that will allow physiological information to be assigned to anatomical locations in MRI space, utilizing non-rigid MRI normalization algorithms.
- To collate and analyze the physiological atlas in a statistical manner that allows doctors to understand and treat brain disease more precisely and based on population data.
|
5000 |
All |
1 Year to 90 Years (Child, Adult, Senior) |
NCT00575081 |
060232 1R01EB006136-01 2R01EB006136 1R41NS063705-01A1 9R42MH100007-03 |
Brain Atlas |
August 2006 |
July 2020 |
July 2020 |
December 17, 2007 |
November 13, 2017 |
|
- Vanderbilt Univeristy
Nashville, Tennessee, United States
|
19 |
NCT03115463 |
Recruiting |
Saturation Targets and Resuscitation in Preterm Trial |
|
- Other: Titration of oxygen during neonatal resuscitation
|
Interventional |
Not Applicable |
- University of Texas Southwestern Medical Center
- American Academy of Pediatrics
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Oxidative Balance Ratio from Baseline
- Reduction in Isoprostane,Isofluran, 8-OHdG and protein carbonyls
- • Reduction in oxygen load in the delivery room
- (and 9 more...)
|
75 |
All |
Child, Adult, Senior |
NCT03115463 |
STU-062014-010 1K23HD083511-01A1 |
STARTPreterm |
September 20, 2017 |
June 2019 |
June 2020 |
April 14, 2017 |
March 5, 2018 |
|
- Parkland Hospital
Dallas, Texas, United States
|
20 |
NCT03142568 |
Recruiting |
Safety of Sildenafil in Premature Infants |
- Bronchopulmonary Dysplasia
|
- Drug: Sildenafil
- Other: Placebo
|
Interventional |
Phase 2 |
- University of North Carolina, Chapel Hill
- Duke University
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- The EMMES Corporation
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety as determined by adverse event experienced by participants
- Volume of Distribution
- Clearance
- (and 4 more...)
|
120 |
All |
up to 28 Days (Child) |
NCT03142568 |
17-2436 HHSN27500039 |
SIL02 |
April 2, 2018 |
June 2019 |
August 2019 |
May 5, 2017 |
April 4, 2018 |
|
- Wesley Medical Center
Wichita, Kansas, United States - Ochsner Baptist Medical Center
New Orleans, Louisiana, United States - Children's Hospital of Nevada at UMC
Las Vegas, Nevada, United States - (and 4 more...)
|
21 |
NCT00071786 |
Recruiting |
Family Study of Affective and Anxiety Spectrum Disorders |
- Mood Disorders
- Anxiety Disorders
|
|
Observational |
|
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
3975 |
All |
up to 60 Years (Child, Adult) |
NCT00071786 |
030211 03-M-0211 |
|
October 30, 2003 |
|
|
October 31, 2003 |
April 25, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|